| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | -15.15% | Piper Sandler | $26 → $17 | Downgrades | Neutral → Underweight |
| 03/02/2020 | 129.6% | Cantor Fitzgerald | $58 → $46 | Maintains | Neutral |
| 03/22/2019 | 104.64% | Mizuho | $40 → $41 | Maintains | Neutral |
| 10/31/2018 | 169.53% | Piper Sandler | $82 → $54 | Downgrades | Overweight → Neutral |
| 09/21/2018 | 299.3% | Cantor Fitzgerald | $81 → $80 | Maintains | Overweight |
What is the target price for Eagle Pharmaceuticals (EGRX)?
The latest price target for Eagle Pharmaceuticals (NASDAQ: EGRX) was reported by Piper Sandler on August 9, 2023. The analyst firm set a price target for $17.00 expecting EGRX to fall to within 12 months (a possible -15.15% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Eagle Pharmaceuticals (EGRX)?
The latest analyst rating for Eagle Pharmaceuticals (NASDAQ: EGRX) was provided by Piper Sandler, and Eagle Pharmaceuticals downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Eagle Pharmaceuticals (EGRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eagle Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eagle Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
Is the Analyst Rating Eagle Pharmaceuticals (EGRX) correct?
While ratings are subjective and will change, the latest Eagle Pharmaceuticals (EGRX) rating was a downgraded with a price target of $26.00 to $17.00. The current price Eagle Pharmaceuticals (EGRX) is trading at is $20.04, which is out of the analyst's predicted range.